CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
2021 · New England Journal of Medicine · 1,558 citations
https://doi.org/10.1056/nejmoa2107454
J
Jörg Täubel
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
149
Papers
4.9K
Citations
23
h-index
51
i10-index
Jörg Täubel is an academic researcher from St George's, University of London. The author has contributed to research in topics: Cardiac electrophysiology and arrhythmias & Receptor Mechanisms and Signaling & ECG Monitoring and Analysis. The author has an h-index of 23, co-authored 127 publications.
ORCID: 0000-0002-0010-207XPapers by this author
worksZilebesiran, an RNA Interference Therapeutic Agent for Hypertension
2023 · New England Journal of Medicine · 232 citations
https://doi.org/10.1056/nejmoa2208391
CRISPR-Cas9 Gene Editing with Nexiguran Ziclumeran for ATTR Cardiomyopathy
2024 · New England Journal of Medicine · 101 citations
https://doi.org/10.1056/nejmoa2412309
Nexiguran Ziclumeran Gene Editing in Hereditary ATTR with Polyneuropathy
2025 · New England Journal of Medicine · 9 citations
https://doi.org/10.1056/nejmoa2510209
Blinding Is Seeing: A Single-Centre Study Into the Viability of Auto-Injectors for Blinded-Drug Administration in Randomised Controlled Trials
2023 · Cureus · 1 citations
https://doi.org/10.7759/cureus.44244
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat